UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2033-15
Program Prior Authorization/Medical Necessity
Medication Hetlioz®, Hetlioz LQ™ (tasimelteon)
P&T Approval Date 7/2014, 5/2015, 5/2016, 5/2017, 5/2018, 5/2019, 5/2020, 5/2021, 12/2021,
12/2022, 1/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Hetlioz is a melatonin receptor agonist indicated for the treatment of non-24-hour sleep-wake
disorder in adults and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in
patients 16 years of age and older. Hetlioz LQ is an oral suspension and is indicated for the
treatment of nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of
age.
Non-24-hour sleep wake disorder is also called free-running disorder, circadian rhythm sleep
disorder – free running (or non-entrained) type, and hypernychthemeral syndrome.
2. Coverage Criteriaa:
A. Initial Authorization
1. Hetlioz or Hetlioz LQ will be approved based on all of the following criteria:
a. One of the following:
(1) Both of the following:
(a) Diagnosis of non-24-hour sleep wake disorder (also known as free-running
disorder, free-running or non-entrained type circadian rhythm sleep disorder,
or hypernychthemeral syndrome)
(b) Patient is totally blind (has no light perception)
-OR-
(2) Diagnosis of nighttime sleep disturbances in Smith-Magenis-Syndrome (SMS)
-AND-
b. One of the following:
(1) History of contraindication or intolerance to melatonin therapy
-OR-
(2) Both of the following:
© 2025 UnitedHealthcare Services, Inc.
1
(a) History of failure of at least 6 monthsb of continuous therapy (i.e.,
uninterrupted daily treatment) with melatonin
-AND-
(b) Continuous trial of melatonin was done under the guidance of a specialist in
sleep disorders
-AND-
c. Prescribed by or in consultation with a specialist in sleep disorders
Authorization will be issued for 12 months.
B. Reauthorization
1. Hetlioz or Hetlioz LQ will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
b For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Hetlioz [package insert]. Washington, D.C.: Vanda Pharmaceuticals Inc.; February 2021.
2. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd
ed. Darien, IL: American Academy of Sleep Medicine; 2014
3. Auger RR, Burgess HJ, Emens JS, et al. Clinical Practice Guidelines for the Treatment of
Intrinsic Circadian Rhythm Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-
Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD) J
Clin Sleep Med 2015;11(10):1199 –1236.
4. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon
(VEC-162) for transient insomnia after sleep-time shift: two randomised controlled
multicentre trials. Lancet. 2009 Feb 7;373(9662):482-91.
© 2025 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Medical Necessity – Hetlioz, Hetlioz LQ (tasimelteon)
Change Control
7/2014 New program.
9/2014 Administrative change - Tried/Failed exemption for State of New
Jersey removed.
5/2015 Annual Review. No changes.
5/2016 Annual review. No changes to clinical intent. Updated background and
references.
7/2016 Added Indiana and West Virginia coverage information.
11/2016 Administrative change. Added California coverage information.
5/2017 Annual review. Added prescriber criteria for reauthorization. Updated
references. Updated state mandate reference language.
5/2018 Annual review. No changes.
5/2019 Annual review. No changes.
5/2020 Annual review. Updated references.
5/2021 Updated to allow coverage of nighttime sleep disturbances in Smith-
Magenis Syndrome based on updated labeling with newly approved
indication. Added Hetlioz LQ to criteria. Removed prescriber requirement
from reauthorization criteria.
12/2021 Updated background and references.
12/2022 Annual review. No changes.
1/2024 Annual review. Updated step therapy mandate note to include Mississippi.
3/2025 Updated initial authorization to 12 months.
© 2025 UnitedHealthcare Services, Inc.
3